作者
NULL AUTHOR_ID,NULL AUTHOR_ID,Marcy B. Bolster,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Dinesh Khanna,Gordon Guyatt,NULL AUTHOR_ID,Rohit Aggarwal,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Hassan Chami,D. Corwin,Paul F. Dellaripa,Robyn T. Domsic,Tracy J. Doyle,NULL AUTHOR_ID,Tracy Frech,Fiona K. Gibbons,Monique Hinchcliff,Clare Johnson,NULL AUTHOR_ID,John S. Kim,Sian Yik Lim,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Lee Shapiro,Claire Sharkey,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Danielle Antin‐Ozerkis,B. Bemiss,NULL AUTHOR_ID,Jane E. Dematte D’Amico,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Gregory McDermott,NULL AUTHOR_ID,Justin M. Oldham,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Stacey Uhl,NULL AUTHOR_ID
摘要
We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.